Storing DSIP: Best Practices
⚠️ Important: DSIP is highly labile. Special handling is required to prevent rapid in vitro degradation by aminopeptidases.
❄️ Lyophilized Powder Storage
Store DSIP (Delta Sleep-Inducing Peptide) lyophilized powder at -20°C for up to approximately 1 year, or at -80°C for up to 2 years. Keep tightly sealed and protected from moisture — DSIP is hygroscopic and will absorb atmospheric water if exposed. Store under desiccation conditions, preferably with a molecular sieve or desiccant pack in the storage container.
🧪 Reconstituted Solution Storage
After reconstitution, store at -20°C for up to 1 month or at -80°C for up to 6 months. Do not store reconstituted DSIP at 4°C for extended periods due to susceptibility to proteolytic degradation. Prepare small aliquots immediately after reconstitution to avoid repeated freeze-thaw cycles, each of which accelerates peptide degradation.
⚗️ Reconstitution Protocol
Reconstitute DSIP in bacteriostatic water or sterile physiological saline (0.9% NaCl). Typical working concentrations in research protocols range from 0.1–1 mg/mL. DSIP is soluble in aqueous buffers. For stock solutions, prepare in smaller volumes (50–100 µL aliquots) and store at -80°C. Avoid glass containers if possible, as DSIP may adsorb to glass surfaces at low concentrations.
⚠️ Degradation Sensitivity
DSIP (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) has an extremely short in vitro half-life of approximately 15 minutes due to rapid N-terminal tryptophan cleavage by aminopeptidases. This fragility is a key pharmacological characteristic that has complicated its study and contributed to variable research results. Plasma stability studies demonstrate rapid degradation into smaller fragments (Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu and further). Handling on ice and minimal exposure to protease-containing environments is critical.
🧬 Physical Characteristics
DSIP is typically supplied as a white lyophilized powder. Molecular weight: 848.83 Da. Standard purity: ≥95–98% by HPLC. Identity confirmed by mass spectrometry. May be supplied as the free acid, acetate salt, or TFA salt — salt form affects net peptide content per stated weight.
For Research Use Only. This product is furnished for in-vitro laboratory studies only. Not approved by the FDA for any medical indication.
“Preclinical Research Summary Key Preclinical Studies StudyModelKey FindingsRef Mu et al.”
References
- Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): A still unresolved riddle. J Neurochem. 2006;97(2):303-309.
- Dick P, Costa C, Fayolle K, et al. DSIP in the treatment of withdrawal syndromes from alcohol and opiates. Eur Neurol. 1984;23(5):364-371.
- Schneider-Helmert D, Gnirss F, Monnier M, Schenker J, Schoenenberger GA. Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. Int J Clin Pharmacol Ther Toxicol. 1981;19(8):341-345.
- Schneider-Helmert D. Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. Eur Neurol. 1987;27(2):120-129.
- Larbig W, Gerber WD, Kluck M, Schoenenberger GA. Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. Eur Neurol. 1984;23(5):372-385.
- Kaeser HE. A clinical trial with DSIP. Eur Neurol. 1984;23(5):386-388.
- Tukhovskaya EA, Ismailova AM, Shaykhutdinova ER, et al. Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke. Molecules. 2021;26(17):5173.
- Tukhovskaya EA, Shaykhutdinova ER, Ismailova AM, et al. DSIP-Like KND Peptide Reduces Brain Infarction in C57Bl/6 and Reduces Myocardial Infarction in SD Rats When Administered during Reperfusion. Biomedicines. 2021;9(4):407.
- Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): a review. Neurosci Biobehav Rev. 1984;8(1):83-93.
- Popovich IG, Voitenkov BO, Anisimov VN, et al. Effect of delta-sleep inducing peptide-containing preparation Deltaran on biomarkers of aging, life span and spontaneous tumor incidence in female SHR mice. Mech Ageing Dev. 2003;124(6):721-731.
- Nakamura A, Nakashima M, Sugao T, et al. Potent antinociceptive effect of centrally administered delta-sleep-inducing peptide (DSIP). Eur J Pharmacol. 1988;155(3):247-253.
- Dick P, Grandjean ME, Tissot R. Successful treatment of withdrawal symptoms with delta sleep-inducing peptide. Neuropsychobiology. 1983;10(4):205-208.
- Scherschlicht RR, Tissot R. Nonapeptide for treating addictive drug withdrawal conditions. US Patent 4,444,758. 1984.
- Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. FDA Website. Updated July 2025.
- Schoenenberger GA. Characterization, properties and multivariate functions of delta-sleep-inducing peptide (DSIP). Eur Neurol. 1984;23(5):321-345.
- Hrnčić D, Stanojlović O, Živanović D, Šušić V. Delta-sleep-inducing peptide potentiates anticonvulsive activity of valproate against metaphit-provoked audiogenic seizure in rats. Pharmacology. 2006;77(2):78-84.
- Monnier M, Dudler L, Gaechter R, et al. The delta sleep inducing peptide (DSIP). Comparative properties of the original and synthetic nonapeptide. Experientia. 1977;33(4):548-552.
- Sudakov KV, Ivanov VT, Koplik EV, et al. Delta-sleep-inducing peptide (DSIP) as a factor facilitating animals' resistance to acute emotional stress. Pavlov J Biol Sci. 1983;18(1):1-5.
- Graf M, Baumann JB, Girard J, et al. DSIP-induced changes of daily concentrations of brain neurotransmitters and plasma proteins in rats. Pharmacol Biochem Behav. 1982;17(3):511-517.
- Shandra AA, Godlevskii RS, Vast'yanov AI, et al. Effect of intranigral dosage with delta-sleep-inducing peptide and its analogs on movement and convulsive activity in rats. Neurosci Behav Physiol. 1996;26(6):567-571.
- Salieva RM, Koplik EV, Kamenov ZA, Poletaev AB. Effects of beta endorphin and delta-sleep inducing peptide on resistance to emotional stress. Biull Eksp Biol Med. 1989;108(10):464-466.
- Mu X, Qu L, Yin L, Wang L, Liu X, Liu D. Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models. Front Pharmacol. 2024;15:1439536.
- Bes F, Hofman W, Schuur J, Van Boxtel C. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology. 1992;26(4):193-197.
Related Research Questions
Related research
Browse all research guides in the Peptide Research Library →Want the complete research review?
View Full DSIP Research Page→FOR RESEARCH USE ONLY
This content is provided for educational and informational purposes only. Products are furnished for in-vitro studies only and are not medicines, drugs, or supplements. Not approved by the FDA to prevent, treat, or cure any condition.
